Skip to main content
Midas Edge

Vistagen Therapeutics, Inc.

For the period ended Dec 31, 2025. Filed Feb 12, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Dec 31, 2025 · Filed Feb 12, 2026

VTGN$0.18+12.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Changes in Stockholders’ Equity

(in thousands, except share amounts)

Common Stock · AdditionalPaid-inCapital · TreasuryStock · AccumulatedOther Comprehensive Income · AccumulatedDeficit · TotalStockholders’Equity
Shares · Amount
Balance at March 31, 202427,029,731$27$474,441$(3,968)$—$(356,214)$114,286
Stock-based compensation expense——1,160———1,160
Sale of common stock pursuant to 2019 Employee Stock Purchase Plan29,898—88———88
Unrealized gain on marketable securities available-for-sale, net————2—2
Net loss—————(10,733)(10,733)
Balance at June 30, 202427,059,629$27$475,689$(3,968)$2$(366,947)$104,803
Stock-based compensation expense——1,112———1,112
Unrealized gain on marketable securities available-for-sale, net————20—20
Net loss—————(12,961)(12,961)
Balance at September 30, 202427,059,629$27$476,801$(3,968)$22$(379,908)$92,974
Stock-based compensation expense——1080———1,080
Sale of common stock pursuant to 2019 Employee Stock Purchase Plan44,906—113———113
Unrealized loss on marketable securities available-for-sale, net————(11)—(11)
Issuance of common stock under Open Market Sale Agreement, net of issuance costs428,32211,054———1,055
Issuance of common stock upon exercise of Pre-Funded Warrants788,359——————
Net loss—————(14,089)(14,089)
Balance at December 31, 202428,321,216$28$479,048$(3,968)$11$(393,997)$81,122
Common Stock · Additional Paid-inCapital · TreasuryStock · AccumulatedOther Comprehensive Income · AccumulatedDeficit · TotalStockholders’Equity
Shares · Amount
Balance at March 31, 202529,001,481$29$481,956$(3,968)$5$(407,632)$70,390
Stock-based compensation expense——916———916
Sale of common stock pursuant to 2019 Employee Stock Purchase Plan95,037—161———161
Issuance of common stock under Open Market Sale Agreement, net of issuance costs190,067—397———397
Unrealized loss on marketable securities available-for-sale, net————(4)—(4)
Net loss—————(15,095)(15,095)
Balance at June 30, 202529,286,585$29$483,430$(3,968)$1$(422,727)$56,765
Stock-based compensation expense——1,096———1,096
Issuance of common stock under Open Market Sale Agreement, net of issuance costs9,608,7721027,872———27,882
Issuance of common stock upon exercise of stock options211——————
Unrealized gain on marketable securities available-for-sale, net————13—13
Net loss—————(19,417)(19,417)
Balance at September 30, 202538,895,568$39$512,398$(3,968)$14$(442,144)$66,339
Stock-based compensation expense——1,096———1,096
Sale of common stock pursuant to 2019 Employee Stock Purchase Plan122,747—70———70
Unrealized loss on marketable securities available-for-sale, net————(1)—(1)
Issuance of common stock under Open Market Sale Agreement, net of issuance costs604,40512,307———2,308
Issuance of common stock upon exercise of stock options2,119—7———7
Net loss—————(18,899)(18,899)
Balance at December 31, 202539,624,839$40$515,878$(3,968)$13$(461,043)$50,920
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.